Bolt Projects Holdings, Inc. Price & Performance (BSLK)

Bolt Projects Holdings has appointed Christine Battist as a new director and audit chair, filling a board vacancy. This leadership change comes as the company grapples with a 96% stock decline over the past year and potential Nasdaq delisting due to market value non-compliance. Battist's financial expertise may prove vital.1

Bolt Projects Holdings reported Q4 2024 revenue of $1.3 million, consistent with the prior quarter but down from 2023 levels. However, operating losses reached $6.5 million due to flat expenses. The company continues to rely on its Vegan Silk Technology Platform to drive growth amid financial challenges.2

Elevation Oncology has announced a 70% workforce reduction following disappointing clinical trial results for its EO-3021 drug candidate. The company will now prioritize its HER3-positive solid tumor treatment, EO-1022, while attempting to conserve cash and explore shareholder value maximization strategies.3